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Abstract: Ocular myositis represents a subgroup within the idiopathic orbital inﬂ  ammatory 
syndrome, formerly termed orbital pseudotumor. Ocular myositis describes a rare inﬂ  ammatory 
disorder of single or multiple extraocular eye muscles. Unilateral or sequential bilateral subacute 
painful diplopia is the leading symptom of eye muscle myositis. There are at least two major 
forms, a limited oligosymptomatic ocular myositis (LOOM) with additional conjunctival injec-
tions only, and a severe exophthalmic ocular myositis (SEOM) with additional ptosis, chemosis, 
and proptosis. Eye muscle myositis is an idiopathic inﬂ  ammation of the extraocular muscles 
in the absence of thyroid disease, ocular myasthenia gravis, and other systemic, particularly 
autoimmune mediated diseases, resembling CD4+ T cell-mediated dermatomyositis. Contrast-
enhanced orbital magnetic resonance imaging most sensitively discloses swelling, signal hyper-
intensity, and enhancement of isolated eye muscles. Typically, corticosteroid treatment results 
in prompt improvement and remission within days to weeks in most patients. Compiled data of 
ﬁ  ve patients and a review of the clinical pattern, diagnostic procedures, differential diagnoses, 
and current treatment options are given.
Keywords: ocular myositis; idiopathic orbital inﬂ  ammation; painful diplopia; enlarged extra-
ocular muscles
Entity, clinical signs and symptoms, and forms 
of ocular myositis
Orbital pseudotumor, ﬁ  rst described by Gleason in 1903 and later termed by Birch-
Hirschﬁ  eld in 1930, is a benign idiopathic inﬂ  ammatory disease that may affect any 
structure in the orbit (Scott and Siatkowski 1997). Today, ocular myositis represents 
a subgroup within the entity of idiopathic orbital inﬂ  ammatory syndrome (IOIS), 
formerly termed orbital pseudotumor. Ocular myositis describes a rare inﬂ  amma-
tory disorder of single or multiple extraocular eye muscles. Primary manifestations 
encompass subacute orbital painful diplopia, exacerbated by eye movement. Diplopia 
is caused by handicapped contraction and distraction of affected eye muscles, not by 
neurogenic affection. In most of the patients, beyond orbital discomfort, no additional 
signs or symptoms are present. There are two major forms, 1) a limited oligosymp-
tomatic ocular myositis (LOOM) with additional conjunctival injections only, and 
2) a severe exophthalmic ocular myositis (SEOM) with additional ptosis, chemosis, 
and proptosis. Furthermore, signs and symptoms of other subgroups of IOIS, such as 
dacryoadentitis, periscleritis, and perineuritis may be evident (Moorman and Elston 
1995; Lacey et al 1999; Jacobs and Galetta 2002; Harris 2006).
Extraocular muscles
Extraocular muscle (EOM) is signiﬁ  cantly different from limb skeletal muscle, but it 
is not precisely known why extraocular muscles are preferentially affected by inﬂ  am-
mation in IOIS. EOMs have smaller motor unit sizes, higher motor neuron discharge Clinical Ophthalmology 2007:1(1) 38
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rates, higher blood ﬂ  ow, and higher mitochondrial volume 
fractions compared with skeletal muscle. This suggests that 
the energy requests and susceptibility to mitochondrial dys-
function are higher as compared with skeletal muscle (Yu 
Wai Man 2005; Schoser and Pongratz 2006). EOMs have a 
unique myoﬁ  brillar protein isoform composition reﬂ  ecting 
their structural and functional properties (Kjellgren et al 
2006). Furthermore, due to the high blood ﬂ  ow and vascu-
larisation, inﬂ  ammatory cells circulate more easily within this 
specialized body compartment (Yu Wai Man 2005; Schoser 
and Pongratz 2006).
Pathogenetic background of ocular 
myositis
Idiopathic variants
Very rarely muscle biopsies of extraocular muscle were 
performed, reporting mixed inﬁ  ltrates of plasma cells, 
lymphocytes, macrophages, and polymorphonuclear cells. 
More chronic forms are associated with ﬁ  brosis. Thus, 
pathogenesis of the so called idiopathic cases are widely 
not investigated. Recently, Gerald Harris (2006) provided 
a perspective paper on idiopathic orbital inﬂ  ammation. The 
monocyte-macrophage line in combination with B-cells 
and helper and effector T-cells have multiple functions. 
Macrophages with major histocompatibility complex mol-
ecules are able to process, present, and initiate a cellular 
immune response. A clonal proliferation of helper cells 
produces cytokines, causing effector T-cells to multiply 
and lyse antigen-bearing cells. Cytokines mobilize and 
activate macrophages in a feedback circle. Beyond lysis of 
cells bearing foreign antigens, they also cause tissue injury 
and ﬁ  brosis. Simultaneously, a B-cell proliferation is initi-
ated with transformation into antibody-producing plasma 
cells. Some bacterial or viral antigens and endotoxins 
can directly activate macrophages or B-cells, leading to 
neutralizing antibodies, but can also cause tissue damage. 
Intracellular antigens may not be fully digested, therefore 
activated macrophages and T-cells proliferate, aggregate, 
and isolate these antigens in a granulomatous pattern. Injury 
or structural similarities can alter the antigenicity of tissue 
speciﬁ  c proteins, which are then recognized as foreign and 
lead to a secondary, autoimmune wave of inﬂ  ammation 
(molecular mimicry) (Dalakas 2006; Harris 2006). In the 
context of ocular myositis, the precise components and tim-
ing of this role model of inﬂ  ammation has to be analyzed 
in future. Some of the known ﬁ  ndings of ocular myositis 
are in line with the current model of the pathogenesis of 
dermatomyositis as a complement-mediated microangiopa-
thy (Dalakas 2006). 
Speciﬁ  c variants
Some cases are associated with speciﬁ  c myositis either by 
bacterial or viral infections (eg, Lyme disease, cysticercosis, 
post-streptococcal, or herpes zoster), or systemic immuno-
mediated disease such as sarcoidosis, systemic lupus 
erythematosus, Crohn´s disease, giant cell arteriitis, and 
linear scleroderma (Lacey et al 1999; Harris 2006). 
Compilation of ﬁ  ve cases
Within the past 10 years, three women and two men, aged 
28 to 66 years (mean 46 years) presented with signs and 
symptoms of ocular myositis in our neuromuscular outpatient 
clinic (Table 1). All had acute to subacute onset of the disease 
with painful diplopia exacerbated by eye movement. Two of 
them presented with the combination of chemosis, ptosis, 
and proptosis (SEOM form; Table 1; Figure 1). Eye muscle 
biopsy was performed in none of the patients, but a biopsy 
of the deltoid muscle was taken without any pathological 
ﬁ  nding in two of the ﬁ  ve patients (data not shown). Axial 
and coronal magnetic resonance imaging (MRI) of the orbits 
showed a multilocal edema and enlargement of different eye 
muscles in all patients (for example see Figure 1, Table 1). 
In two patients only the medial rectus muscle was affected. 
Figure 1 Coronal MRI (T2 left (A, C); contrast-enhanced T2 right (B, D, C, and D 
detail from A, B respectively) view of a patient with ocular myositis. Most promi-
nent is the edema and swelling of the left inferior rectus muscle, although other 
eye muscles are also involved (A–D). This 48-year-old women developed horizontal 
diplopia over a 5-day period, which was associated with dull retroorbital pain. She 
showed 5 mm of axial proptosis, chemosis, tenderness, and restricted ductions on 
the left side (SEOM patient). Treatment with corticosteroids was initiated, and after 
10 weeks azathioprine was added, leading to complete remission of the symptoms 
within 7 month. 
Abbreviations: MRI, magnetic resonance imaging; SEOM, severe exophthalmic 
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Two patients showed a recurrent disease course on the same 
side after one year, while tapering corticosteroid treatment. In 
the other three patients, after initiation of immunosuppressive 
therapy using corticosteroids (1.0 mg/kg/d) and azathioprine 
(up to 150 mg), within 4 weeks, a complete recovery from 
all symptoms was evident (Table 1). 
Summary of data given 
in the literature
The frequency of major symptoms are acute to subacute 
orbital and/or retroorbital pain (~95%), diplopia (~85%), 
conjunctival injections closely related to the affected eye 
muscle (~70%), and proptosis (~60%) (Weinstein et al 1983; 
Moorman and Elston 1995; Berkhoff et al 1997; Lacey 
et al 1999). Recurrence can involve different muscles, and 
sporadically alternate the eye (~30%) (Moorman and Elston 
1995; Berkhoff et al 1997; Lacey et al 1999). Overall, there 
seems to be a slightly predominance of the disease in females 
(2:1) (Moorman and Elston 1995; Berkhoff et al 1997; Lacey 
et al 1999). The mean age at onset is around age 40 (range 
7–80 years). Imaging studies corroborate that no particular 
pattern of muscle involvement is found. Unilateral single 
muscle inﬂ  ammation with tendon involvement is the most 
common presentation. Nevertheless, superior, lateral, and 
medial rectus muscles are more often affected than inferior 
rectus muscle (Lacey et al 1999). Multiple involvements at 
initial presentation seemed to be a risk factor for recurrence, 
particularly if bilateral. During repeated attacks, additional 
muscles are often involved (Lacey et al 1999; see Table 2 
for summary).
Diagnostic assessment
High-resolution orbital computed tomography is not as sensi-
tive as MRI. When available, contrast-enhanced MRI with 
multiple coronal views and fat saturation should be the initial 
diagnostic study performed (Jacobs and Galetta 2002). Eye 
muscle biopsy or limb muscle biopsy is usually not indicated, 
and response to therapy frequently conﬁ  rms the diagnosis. 
Other additional blood analyses are recommended regarding 
to optional differential diagnoses. 
Differential diagnoses of ocular 
myositis
Thyroid associated orbitopathy
Thyroid orbitopathy is thought to be an organ-specific 
autoimmune process and is associated with thyroid disease in 
80%–90% of cases. Thyroid orbitopathy is the most common 
cause of orbital disease (Jacobs and Galetta 2002; Garrity and 
Bahn 2006). Characteristically, the onset is insidious rather 
than acute. Lid lag and lid retraction in down-gaze are two 
characteristic ﬁ  ndings of this disorder (Jacobs and Galetta 
2002; Garrity and Bahn 2006). Bilateral muscle involvement 
including inﬂ  ammation, edema, and secondary ﬁ  brosis is 
very common. Imaging reveals fusifom posterior enlarge-
ment of extraocular muscles with relative sparing of the 
tendon (Lacey et al 1999; Jacobs and Galetta 2002; Garrity 
and Bahn 2006). Optic neuropathy is a serious complication 
of thyroid eye disease, but is relatively uncommon, with 
Table 1 Summary of ﬁ  ve patients with ocular myositis
Age of onset (mean, range, years)  46 (28-66)
Sex 3  female/2  male 
More than one muscle affected  3/5 (60%)
Bilateral manifestation (sequential)  2/5 (40%)
Medial rectus affection  5/5 (100%)
Superior rectus affection  3/5 (60%)
Lateral rectus affection  2/5 (40%)
Inferior rectus affection  1/5 (20%)
LOOM form (3 of 5 patients)
Subacute onset of retrobulbar/orbital pain  3/3 (100%)
Diplopia 3/3  (100%)
Conjunctival injections  2/3 (66%)
Ptosis 0/3  (0%)
Proptosis 0/3  (0%)
SEOM form (2 of 5 patients)
Subacute onset of retrobulbar/orbital pain  2/2 (100%)
Diplopia 2/2  (100%)
Ptosis 1/2  (50%)
Chemosis 2/2  (100%)
Proptosis 2/2  (100%)
Abbreviations: LOOM, limited oligosymptomatic ocular myositis; SEOM, severe 
exophthalmic ocular myositis. 
Table 2 Summary of the frequency of symptoms in ocular 
myositis
General aspects
Age of onset (years, range)  30–40 (7–80)
Sex (ratio)  female > male (2:1)
More than one muscle affected  50%
Bilateral manifestation (sequential)  30%
Medial rectus affection  70%
LOOM form (75% of all patients)
Subacute onset of retrobulbar/orbital pain  95%
Exacerbation of retrobulbar pain by eye   90%
movement
Diplopia 85%
Conjunctival injections  75%




Abbreviations: LOOM, limited oligosymptomatic ocular myositis; SEOM, severe 
exophthalmic ocular myositis. Clinical Ophthalmology 2007:1(1) 40
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visual loss occurring in up to 5% of Graves’ orbitopathy 
patients. Impairment of colour vision, optic disc swelling, 
and radiological evidence of apical optic nerve compression 
are the major features of this severe complication of thyroid 
eye disease (McKeag et al 2007) (Table 3).
Ocular myasthenia gravis 
The term ocular myasthenia contrasting generalized myas-
thenia is to deﬁ  ne the clinical subtype of myasthenia gravis 
with isolated eye muscle weakness with blepharoptosis or 
ophthalmoparesis, resulting in diplopia. Ocular dysfunction 
accounts for 50%–80% of the initial manifestation of myas-
thenia gravis. Asymmetric ptosis is most frequently related to 
acquired autoimmune myasthenia gravis. Moreover, inherited 
congenital myasthenic syndromes are frequently associated 
with ptosis and ophthalmoplegia. The eyelid ice test, edro-
phonium test, and nerve conduction studies with repetitive 
nerve stimulation of the facial nerves are supportive in making 
the diagnosis. Additionally, acetylcholine receptor antibodies 
are present in 40%–60% of the patients (Elrod and Weinberg 
2004; Beeson et al 2005; Romi et al 2005) (Table 3).
Tolosa-Hunt syndrome
This syndrome of painful ophthalmoplegia consists of peri-
orbital or hemicranial pain, combined with ipsilateral ocular 
motor nerve palsies, oculosympathetic paralysis, and sensory 
loss in the distribution of the ophthalmic and occasionally 
the maxillary division of the trigeminal nerve. Multiple 
combinations of cranial nerve palsies may occur, localizing 
the pathological process to the region of the cavernous 
sinus/superior orbital ﬁ  ssure. The Tolosa-Hunt syndrome 
is caused by an inﬂ  ammatory process with granulomatous 
inﬂ  ammation, epithelioid cells, and occasional giant cells 
(Kline and Hoyt 2001). Spontaneous remissions may occur; 
corticosteroids markedly reduce the pain and syndrome.
Oculopharyngeal muscular dystrophy 
The combination of ptosis and pharyngeal weakness com-
bined with ophthalmoparesis, dysphagia, and weakness and 
wasting of face, neck, proximal, and distal limb muscles 
characterizes the autosomal dominant, late-onset oculopha-
ryngeal muscular dystrophy (OPMD). OPMD is caused by 
expansions in a 6 GCG trinucleotide repeat tract located in 
the ﬁ  rst exon of the polyadenylate binding protein nuclear 
1 gene on chromosome 14q (Brais 2003; Ruegg et al 2005). 
Genetic testing is available (Table 3). 
Myotonic dystrophy type 1 (DM1)
Among the well known multisystemic features of the classic 
from of myotonic dystrophy (DM1) eg, muscle weakness and 
myotonia, the eye is affected in multiple ways. Not only the 
myotonic cataracts, but also retinal abnormalities, ptosis, and 
blepharospasm are common features of the disease. DM1 is 
caused by expansions in CTG trinuclotide repeat tract located 
in the myotonic dystrophy protein kinase gene on chromo-
some 19q. To exclude this disease, genetic testing is available 
(Harper 2001; Schara and Schoser 2006) (Table 3).
Congenital cranial dysinnervation 
disorders and congenital ﬁ  brosis 
of extraocular muscles
The congenital cranial dysinnervation disorders (CCDDs) 
encompass congenital, nonprogessive, sporadic, or famil-
Table 3 Differential diagnoses of ocular myositis
 OM  TED  Ocular  MG  OPMD  DM1  PEO
Ptosis +  +  +++  +++  ++  ++
Proptosis +  +++  - -  -  -
Diplopia ++  +  +++  -/+  -/+  -/+
Laterality
 - unilateral  ++  +  ++  +  +  +
 - bilateral  +  ++  +  ++  ++  ++
Orbital pain  ++  +  -  -  -  -
Chemosis +  +  + -  -  -
Conjunctival Injection  +  +  +  -  -  -
Systemic symptoms  -/+  +  -  +  +  +
Vision impaired  -  -/+  -  -  -  -
CK elevation  -  -  -  +  +  -/+
Antibodies -  +  +  -  -  -
Notes: Semiquantitative rating of signs and symptoms: - = absent; -/+ = minimal/rare; + = mild/infrequent; ++ = moderate/frequent; +++ = severe/most frequent.
Abbreviations: CK, creatine kinase; DM1, myotonic dystrophy type 1; Ocular MG, ocular myasthenia gravis; OM, ocular myositis; OPMD, oculopharygeal muscular dystro-
phy; PEO, progressive external ophthalmoplegia; TED, thyroid eye disease.Clinical Ophthalmology 2007:1(1) 41
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ial abnormalities of cranial musculature that result from 
developmental abnormalities of, or complete absence of, one 
or more cranial nerves with primary or secondary muscle 
dysinnervation. Among CCDDs, the congenital ﬁ  brosis of 
the extraocular muscles (CFEOM) are rare inherited strabis-
mus syndromes presenting with congenital, nonprogressive 
bilateral ophthalmoplegias with active and passive restriction 
of globe movement, and ﬁ  brosis of the extraocular muscles 
innervated by the oculomotor and/or trochlear nerves. At 
least three distinct syndromes are recognized: CEFOM1 is 
an autosomal dominant form and caused by mutations in the 
KIF21a gene on chromosome 12p. CFEOM2 is an autosomal 
recessive form and homozygous mutations in the ARIX 
gene on chromosome 11q are found. CFEOM3 is mapped 
in separate families to different loci on chromosomes 12q, 
13q, and 16q (Engle 2002; Bau and Zierz 2005; Schoser and 
Pongratz 2006).
Mitochondrial myopathies
The most common form is late onset bilateral progressive 
external ophthalmoplegia (PEO). PEO onset ranges between 
age 11 and 82 years. PEO is characterized by ptosis and 
weakness of extraocular muscles leading to limitation of 
extraocular movements with relative sparing of downgaze, 
and occasionally dysconjugate ocular movements. Although 
transient diplopia may occur, the majority of patients rarely 
complain diplopia and are mostly unaware of their restric-
tions. Ptosis and ophthalmoplegia may occur jointly, but 
each can occur alone. The ptosis is often asymmetric. Up to 
90% of PEO patients have additional weakness of the facial, 
bulbar, or limb muscles. Thus, many patients might be clas-
siﬁ  ed as “PEO plus” by presenting additional multisystemic 
symptoms such as other neurological symptoms, hearing 
disturbances, or diabetes. In about 15% of PEO autosomal 
dominant or recessive inheritance is noticed. Autosomal 
dominant PEO (adPEO) is characterized by accumulation of 
multiple deletions of mtDNA in patient’s tissue. Autosomal 
recessive PEO is rarely found. Clinically, no differences 
between hereditary and sporadic PEO can be elaborated, 
thus further information may be only be found in family 
history (DiMauro and Hirano 2005; Schoser and Pongratz 
2006). The Kearns-Sayre Syndrome (KSS)/PEO Plus is 
characterized by onset before age 20 years and encompasses 
PEO, atypical pigmentary retinopathy (salt- and pepper-like 
appearance), and often myopathic weakness, heart block, 
cerebellar ataxia, and high cerebrospinal ﬂ  uid (CSF) protein 
levels. KSS might include concomitant strabismus, mental 
deterioration, pyramidal signs, short stature, diabetes, or 
delayed sexual maturation (DiMauro and Hirano 2005; 
Schoser and Pongratz 2006). The mitochondrial myopathy 
and encephalopathy, with lactate acidosis, and stroke-like 
episodes (MELAS) was introduced in 1984 to designate 
one of the most common maternally-inherited mitochondrial 
syndromes. At an age of onset between 3 to 40 years, early 
symptoms include muscle weakness (87%), easy fatigability 
(15%–18%), recurrent headaches and seizures (28%). The 
typical clinical manifestations of MELAS include stroke-like 
episodes (99%–100%), seizures (85%–96%), short stature 
(55%–100%), muscle weakness (87%–89%), headache/vom-
iting (77%–92%), hearing loss (27%–75%), encephalopathy 
(20%–95%), optic atrophy (20%), pigmentary retinopathy 
(16%), and PEO (13%) (Dimauro and Hirano 2005; Schoser 
and Pongratz 2006). In patients with the rare sensory ataxic 
neuropathy with dysarthria and ophthalmoparesis (SANDO) 
compound heterozygosity for 2 mutations and homozygous 
mutations in the POLG gene were found. Lately, a hetero-
zygous mutation in the C10ORF2 gene was found. The 
ﬁ  nding indicated that SANDO is a variant of autosomal 
recessive PEO (Hudson et al 2005; Schoser and Pongratz 
2006). Finally, external ophthalmoplegia may also occur as 
a symptom in mitochondrial syndromes such as, myoclonic 
epilepsy, myopathy with ragged red ﬁ  bers (MERRF), mito-
chondrial neurogastrointestinal encephalopathy (MNGIE), 
and neuropathy, ataxia, retinopathia pigmentosa (NARP) 
(Schoser and Pongratz 2006). A muscle biopsy is still needed 
for making the diagnosis in patients with PEO and KSS/PEO 
Plus. Taking a biopsy of a proximal limb muscle instead 
of an extraocular muscle is recommended. Southern blot 
analysis of muscle DNA as a ﬁ  rst step is useful to test single 
or multiple deletions. In some cases with multiple mtDNA 
deletions and autosomal inheritance molecular analysis of 
POLG1, Twinkle and ANT1 are suggested (Table 3).
Current treatment options 
of ocular myositis
Typically, oral corticosteroid treatment (1.0 to 1.5 mg/kg/d 
for 1 to 2 weeks and then taper dosage to zero over 6 to 
12 weeks) results in prompt improvement and remission 
within days to weeks in most patients. Beyond corticoste-
roids, other immunosuppressives are helpful in tapering 
corticosteroid doses in selected patients. Antimetabolites, 
such as azathioprine, methotrexat, mycophenolate mofetil 
are frequently used immunosuppressives in this condition, 
but T-cell inhibitors (eg, cyclosporine, tacrolimus) have also 
been used in a few cases (Lacey et al 1999; Franczo et al 
2006; Harris 2006). Additionally, the use of tumor necrosis Clinical Ophthalmology 2007:1(1) 42
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factor alpha blocker and other new monoclonal antibodies 
are anecdotally reported (Franczo et al 2006; Harris 2006). 
Besides, in selected cases, particularly with recurred and 
severe disease manifestation, high dose of intravenous 
immunoglobulin or rituximab (CD-20 antibody) infusion 
may be helpful (Lacey et al 1999; Dalakas 2006; Franczo 
et al 2006; Harris 2006). 
Conclusions
Although ocular myositis is a rare disease, prompt recogni-
tion, diagnosis, and treatment is important. The most sensitive 
diagnostic tool is the axial and coronal MRI of the orbit. In 
addition assessment of thyroid hormones and antibodies, and 
acetylcholine receptor antibody is suggested. First-line treat-
ment option is corticosteroid therapy. Without prompt relief 
within the next 4 weeks, addition of other immunosuppres-
sive agents is recommended. Nevertheless, the underlying 
pathogenetic mechanism of idiopathic eye muscle myositis 
remains to be elucidated.
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